Skip to main content

Advertisement

SpringerLink
Log in

An Integrative Approach to Pediatric Headache Management: Nutraceuticals

  • Neurology (D Stephenson, Section Editor)
  • Published:
Current Pediatrics Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this paper is to familiarize readers with the breadth of nutraceutical options available to patients that may empower autonomous headache management and lessen headache burden with a low potential for adverse effects.

Recent Findings

Over recent years, the demand and evidence for complementary and alternative medicine (CAM) options in the form of nutraceuticals has grown. Recent data also suggests the benefits of placebo may be equivalent when compared to first-line headache preventive medications in children.

Summary

While medications are often the mainstay of treatment for headache management, the evidence to support medication use in children continues to be weakened by high placebo rates. Patients are increasingly using nutraceuticals with or without physician input. The mechanisms of these therapies are often unclear, but placebo responses are likely involved. Given the high tolerability and low side effect profile reported in nutraceutical trials, these treatments may represent an opportunity to elicit the placebo response in this population, serving as an alternative or complement to medications. Future trials designed to compare nutraceuticals and first-line headache preventive medications would assist in clarifying relative efficacy and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sonal Sekhar M, Sasidharan S, Joseph S, Kumar A. Migraine management: how do the adult and paediatric migraines differ? Saudi pharmaceutical journal : SPJ: the official publication of the Saudi Pharmaceutical Society. 2012;20(1):1–7. doi:10.1016/j.jsps.2011.07.001.

    CAS  Google Scholar 

  2. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Developmental medicine & child neurology. 2010;52(12):1088–97. doi:10.1111/j.1469-8749.2010.03793.x.

    Article  Google Scholar 

  3. Vohra S, Surette S, Mittra D, Rosen LD, Gardiner P, Kemper KJ. Pediatric integrative medicine: pediatrics’ newest subspecialty? BMC Pediatr. 2012;12(1):123. doi:10.1186/1471-2431-12-123.

    Article  PubMed  PubMed Central  Google Scholar 

  4. • Kristoffersen ES, Aaseth K, Grande RB, Lundqvist C, Russell MB. Self-reported efficacy of complementary and alternative medicine: the Akershus study of chronic headache. The journal of headache and pain. 2013;14(1):1–5. doi:10.1186/1129-2377-14-36. It was important to establish the prevelance of CAM use among migraineurs

    Article  Google Scholar 

  5. Gaul C, Eismann R, Schmidt T, May A, Leinisch E, Wieser T, et al. Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia. 2009;29(10):1069–78. doi:10.1111/j.1468-2982.2009.01841.x.

    Article  CAS  PubMed  Google Scholar 

  6. •• Dalla Libera D, Colombo B, Pavan G, Comi G. Complementary and alternative medicine (CAM) use in an Italian cohort of pediatric headache patients: the tip of the iceberg. Neurol Sci. 2014;35(S1):145–8. doi:10.1007/s10072-014-1756-y. This is important to establish the prevelance of CAM use among pediatric migraineurs. This paper also highlighted types of CAM used, reasons for CAM use and lack of communication to healthcare providers regarding CAM use

    Article  PubMed  Google Scholar 

  7. MacLennan SC, Wade FM, Forrest KML, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300.

    Article  PubMed  Google Scholar 

  8. Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29(4):436–44. doi:10.1111/j.1468-2982.2008.01752.x.

    Article  CAS  PubMed  Google Scholar 

  9. •• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2016; doi:10.1056/NEJMoa1610384. This study demonstrated that first-line preventative medications may be no more effective than placebo for pediatric migraine. These findings suggest the need for a shift in our current pharmacological treatment approach

  10. • Schedlowski M, Enck P, Rief W, Bingel U. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev. 2015;67(3):697. In order to validate placebo as a treatment strategy, it is important to review scientific advancements in proposed placebo mechanisms of action

    Article  PubMed  Google Scholar 

  11. Miller FG, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioeth. 2009;9(12):39–47. doi:10.1080/15265160903316263.

    Article  PubMed  Google Scholar 

  12. •• Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5-ra5. doi:10.1126/scitranslmed.3006175. Evidence of successful placebo responses in the setting of full disclosure negates the need to deceive patients when presenting placebo as a viable treatment option. This may help practitioners to overcome the ethical hurdle to placebo use

    Article  Google Scholar 

  13. Chauhan B, Kumar G, Kalam N, Ansari SH. Current concepts and prospects of herbal nutraceutical: a review. Journal of advanced pharmaceutical technology & research. 2013;4(1):4–8. doi:10.4103/2231-4040.107494.

    Article  CAS  Google Scholar 

  14. Barnes PMMA, Bloom B, Nahin RL, National Center for Health S. Complementary and alternative medicine use among adults and children: United States, 2007. vol Book, Whole. Hyattsville, MD-eBook: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2008.

  15. •• Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56(4):808-n/a. doi:10.1111/head.12789. This article summarized existing guidelines pertaining to the use of nutraceuticals for adults with migraine headaches. Since there is less evidence availbale in pediatric migraineurs, treatment strategies are frequently extrapolated from adult data

    Article  Google Scholar 

  16. Smithers G, Gregory JR, Bates CJ, Prentice A, Jackson LV, Wenlock R. The National Diet and Nutrition Survey: young people aged 4–18 years. Nutr Bull. 2000;25(2):105–11. doi:10.1046/j.1467-3010.2000.00027.x.

    Article  Google Scholar 

  17. Colombo B, Saraceno L, Comi G. Riboflavin and migraine: the bridge over troubled mitochondria. Neurol Sci. 2014;35(S1):141–4. doi:10.1007/s10072-014-1755-z.

    Article  PubMed  Google Scholar 

  18. Markley HG. CoEnzyme Q10 and riboflavin: the mitochondrial connection. Headache: The Journal of Head and Face Pain. 2012;52:81–7. doi:10.1111/j.1526-4610.2012.02233.x.

    Article  Google Scholar 

  19. Taylor FR. Nutraceuticals and headache: the biological basis. Headache: The Journal of Head and Face Pain. 2011;51(3):484–501. doi:10.1111/j.1526-4610.2011.01847.x.

    Article  Google Scholar 

  20. Hershey AD, Powers SW, Vockell ALB, LeCates SL, Ellinor PL, Segers A, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache: the journal of head and face pain. 2007;47(1):73–80. doi:10.1111/j.1526-4610.2007.00652.x.

    Article  Google Scholar 

  21. Doring F, Schmelzer C, Lindner I, Vock C, Fujii K. Functional connections and pathways of coenzyme Q10-inducible genes: an in-silico study. IUBMB Life. 2007;59(10):628–33. doi:10.1080/15216540701545991.

    Article  PubMed  Google Scholar 

  22. • Orr SL, Venkateswaran S. Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations. Cephalalgia. 2014;34(8):568–83. doi:10.1177/0333102413519512. This article provides proposed mechanisms of action for select nutraceuticals on migraine prevention

    Article  PubMed  Google Scholar 

  23. Harel Z, Gascon G, Riggs S, Vaz R, Brown W, Exil G. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health. 2002;31(2):154–61. doi:10.1016/S1054-139X(02)00349-X.

    Article  PubMed  Google Scholar 

  24. • Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res. 2014;47(4):349–54. doi:10.1590/1414-431X20143606. This study revealed the need for additional exploration into the use of vitamin D as an adjunctive therapy for migraine prevention in children

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia. 2005;25(6):403–11. doi:10.1111/j.1468-2982.2005.00889.x.

    Article  CAS  PubMed  Google Scholar 

  26. Di Rosa G, Attinà S, Spanò M, Ingegneri G, Sgrò DL, Pustorino G, et al. Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. Headache: the journal of head and face pain. 2007;47(9):1342–4. doi:10.1111/j.1526-4610.2007.00932.x.

    Article  Google Scholar 

  27. Borhani Haghighi A, Motazedian S, Rezaii R, Mohammadi F, Salarian L, Pourmokhtari M, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010;64(4):451. doi:10.1111/j.1742-1241.2009.02215.x.

    Article  CAS  PubMed  Google Scholar 

  28. • Rafie S, Namjoyan F, Golfakhrabadi F, Yousefbeyk F, Hassanzadeh A. Effect of lavender essential oil as a prophylactic therapy for migraine: a randomized controlled clinical trial. Journal of Herbal Medicine. 2016, 6(1):18–23. doi:10.1016/j.hermed.2016.01.003. This study is important that it offers a novel approach for headache prevention deserving of further reasearch

  29. Cianchetti C. Capsaicin jelly against migraine pain. Int J Clin Pract. 2010;64(4):457. doi:10.1111/j.1742-1241.2009.02294.x.

    Article  CAS  PubMed  Google Scholar 

  30. Fattori V, Hohmann MSN, Rossaneis AC, Pinho-Ribeiro FA, Verri WA. Capsaicin: current understanding of its mechanisms and therapy of pain and other pre-clinical and clinical uses. Molecules (Basel, Switzerland). 2016;21(7):844. doi:10.3390/molecules21070844.

    Article  Google Scholar 

  31. •• Chiu H-Y, Yeh T-H, Huang Y-C, Chen P-Y. Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain physician. 2016;19(1):E97. This meta-analysis supports further exploration of the efficacy and safety of magnesium in children given the success in adults

    PubMed  Google Scholar 

  32. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache: The Journal of Head and Face Pain. 2003;43(6):601–10. doi:10.1046/j.1526-4610.2003.03102.x.

    Article  Google Scholar 

  33. • Gallelli L, Avenoso T, Falcone D, Palleria C, Peltrone F, Esposito M, et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache: the journal of head and face pain. 2014;54(2):313–24. doi:10.1111/head.12162. This study supports trialing magnesium in children for migraine prevention

    Article  Google Scholar 

  34. Grazzi L, Andrasik F, Usai S, Bussone G. Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up. Neurol Sci. 2007;28(3):148–50. doi:10.1007/s10072-007-0808-y.

    Article  CAS  PubMed  Google Scholar 

  35. Grazzi L, Andrasik F, Usai S, Bussone G. Magnesium as a treatment for paediatric tension-type headache: a clinical replication series. Neurol Sci. 2005;25(6):338–41. doi:10.1007/s10072-004-0367-4.

    Article  CAS  PubMed  Google Scholar 

  36. Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897–905. doi:10.1177/0333102411406755.

    Article  PubMed  Google Scholar 

  37. DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC. Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol. 2013;39(5):458–84. doi:10.1111/nan.12020.

    Article  CAS  PubMed  Google Scholar 

  38. Knutsen KV, Madar AA, Brekke M, Meyer HE, Natvig B, Mdala I, et al. Effect of vitamin D on musculoskeletal pain and headache: a randomized, double-blind, placebo-controlled trial among adult ethnic minorities in Norway. Pain. 2014;155(12):2591–8. doi:10.1016/j.pain.2014.09.024.

    Article  CAS  PubMed  Google Scholar 

  39. Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014;99(4):1132–41. doi:10.1210/jc.2013-3655.

    Article  CAS  PubMed  Google Scholar 

  40. Salvesen R, Odeh F, Bekkelund SI, Alstadhaug KB. Neurology: prophylaxis of migraine with melatonin: a randomized controlled trial. Altern Med Rev. 2011;16(1):88.

    Google Scholar 

  41. • Gonçalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87(10):1127–32. doi:10.1136/jnnp-2016-313458. This trial presents preliminary support for the use of melatonin for headache prevention

    Article  PubMed  PubMed Central  Google Scholar 

  42. • Bougea A, Spantideas N, Lyras V, Avramidis T, Thomaidis T. Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. Funct Neurol. 2016;31(1):33–7. This trial presents preliminary support for the use of melatonin for headache prevention

    PubMed  PubMed Central  Google Scholar 

  43. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008;29(4):285–7. doi:10.1007/s10072-008-0983-5.

    Article  PubMed  Google Scholar 

  44. • Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132–5. This trial presents preliminary support for the use of melatonin for headache prevention in pediatric patients

    Article  CAS  PubMed  Google Scholar 

  45. Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. The journal of headache and pain. 2009;10(5):361–5. doi:10.1007/s10194-009-0142-2.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomized, double blind, cross-over trial. Cephalalgia. 2010;30(12):1426–34.

    Article  PubMed  Google Scholar 

  47. Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008;1237:35–43. doi:10.1016/j.brainres.2008.08.078.

    Article  CAS  PubMed  Google Scholar 

  48. Harel Z, Riggs S, Vaz R, White L, Menzies G. Omega-3 polyunsaturated fatty acids in adolescents: knowledge and consumption. J Adolesc Health. 2001;28(1):10–5. doi:10.1016/S1054-139X(00)00179-8.

    Article  CAS  PubMed  Google Scholar 

  49. • Menon S, Nasir B, Avgan N, Ghassabian S, Oliver C, Lea R, et al. The effect of 1 mg folic acid supplementation on clinical outcomes in female migraine with aura patients. The Journal of Headache and Pain. 2016;17(1):1–7. doi:10.1186/s10194-016-0652-7.

    Article  CAS  Google Scholar 

  50. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics. 2009;19(6):422–8. doi:10.1097/FPC.0b013e32832af5a3.

    Article  CAS  PubMed  Google Scholar 

  51. Acar A, Evliyaoğlu O, Uzar E, Yücel Y, Çevik MU, Güzel I, et al. Serum vitamin B12, folic acid and ferritin levels in patients with migraine. Türk Nöroloji Dergisi. 2011;17(2):90–5.

    CAS  Google Scholar 

  52. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia: an international journal of headache. 1996;16(4):257.

    Article  CAS  Google Scholar 

  53. Köseoglu E, Talaslioglu A, Gönül AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008;21(2):101.

    PubMed  Google Scholar 

  54. Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22(2):137–41. doi:10.1046/j.1468-2982.2002.00335.x.

    Article  CAS  PubMed  Google Scholar 

  55. Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–5. doi:10.1212/01.WNL.0000151975.03598.ED.

    Article  PubMed  Google Scholar 

  56. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50(2):466–70.

    Article  CAS  PubMed  Google Scholar 

  57. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004;11(7):475–7. doi:10.1111/j.1468-1331.2004.00813.x.

    Article  CAS  PubMed  Google Scholar 

  58. Gaul C, Diener H-C, Danesch U, On behalf of the Migravent® study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. The journal of headache and pain 2015;16(1):1–8. doi:10.1186/s10194-015-0516-6.

  59. Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, Launay JM, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia. 2001;21(8):818–22. doi:10.1046/j.1468-2982.2001.218240.x.

    Article  CAS  PubMed  Google Scholar 

  60. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–53. doi:10.1212/WNL.0b013e3182535d0c.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45(3):196–203. doi:10.1111/j.1526-4610.2005.05044.x.

    Article  PubMed  Google Scholar 

  62. Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain. 2008;12(3):301–13. doi:10.1016/j.ejpain.2007.06.003.

    Article  PubMed  Google Scholar 

  63. •• Prieto JM. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Botanics: targets and therapy. 2014;2014:1–9. doi:10.2147/BTAT.S54023. This article is important in that it reviews the safety concerns surrounding purified versions of the herb Butterbur

    Google Scholar 

  64. Schiapparelli P, Allais G, Castagnoli Gabellari I, Rolando S, Terzi MG, Benedetto C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol Sci. 2010;31(S1):137–9. doi:10.1007/s10072-010-0307-4.

    Article  Google Scholar 

  65. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH, the I. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25(11):1031–1041. doi:10.1111/j.1468-2982.2005.00950.x.

  66. Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesicTMM) in the treatment of migraine. Headache: The Journal of Head and Face Pain. 2011;51(7):1078–86. doi:10.1111/j.1526-4610.2011.01910.x.

    Article  Google Scholar 

  67. Sasannejad P, Saeedi M, Shoeibi A, Gorji A, Abbasi M, Foroughipour M. Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial. Eur Neurol. 2012;67(5):288. doi:10.1159/000335249.

    Article  CAS  PubMed  Google Scholar 

  68. Soltani R, Soheilipour S, Hajhashemi V, Asghari G, Bagheri M, Molavi M. Evaluation of the effect of aromatherapy with lavender essential oil on post-tonsillectomy pain in pediatric patients: a randomized controlled trial. Int J Pediatr Otorhinolaryngol. 2013;77(9):1579–81. doi:10.1016/j.ijporl.2013.07.014.

    Article  PubMed  Google Scholar 

  69. Ghods AA, Abforosh NH, Ghorbani R, Asgari MR. The effect of topical application of lavender essential oil on the intensity of pain caused by the insertion of dialysis needles in hemodialysis patients: a randomized clinical trial. Complementary Therapies in Medicine. 2015;23(3):325–30. doi:10.1016/j.ctim.2015.03.001.

    Article  PubMed  Google Scholar 

  70. Göbel H, Schmidt G, Soyka D. Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters. Cephalalgia : an international journal of headache. 1994;14(3):228.

    Article  Google Scholar 

  71. Göbel H, Fresenius J, Heinze A, Dworschak M, Soyka D. Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type. Nervenarzt. 1996;67(8):672.

    Article  PubMed  Google Scholar 

  72. Borhani Haghighi A, Motazedian S, Rezaie R, Mohammadi F, Salarian L, Pourmokhtari M, et al. FP58-FR-03 cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura. J Neurol Sci. 2009;285:S149-S. doi:10.1016/S0022-510X(09)70577-5.

    Article  Google Scholar 

  73. Kligler B, Chaudhary S. Peppermint oil. United States. 2007. p. 1027–30.

  74. Anand KS, Dhikav V. Migraine relieved by chilis. Headache: The Journal of Head and Face Pain. 2012;52(6):1041. doi:10.1111/j.1526-4610.2012.02180.x.

    Article  Google Scholar 

  75. Levin M. Herbal treatment of headache. Headache: the journal of head and face pain. 2012;52:76–80. doi:10.1111/j.1526-4610.2012.02234.x.

    Article  Google Scholar 

  76. Du Y, Knopf H. Paediatric homoeopathy in Germany: results of the German health interview and examination survey for children and adolescents (KiGGS). Pharmacoepidemiol Drug Saf. 2009;18(5):370–9. doi:10.1002/pds.1720.

    Article  PubMed  Google Scholar 

  77. Stub T, Musial F, Kristoffersen AA, Alræk T, Liu J. Adverse effects of homeopathy, what do we know? A systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2016;26:146–63. doi:10.1016/j.ctim.2016.03.013.

    Article  PubMed  Google Scholar 

  78. Piraneo S. Unicist homeopathy and primary headache. Homoeopathic Links. 2014;27(4):252–5. doi:10.1055/s-0034-1383200.

    Article  Google Scholar 

  79. Administration USFaD. Dietary Supplements. 2016. http://www.fda.gov/Food/DietarySupplements/

  80. Convention TUSP. USP Verified Mark. 2016. http://www.usp.org/verification-services/usp-verified-mark.

  81. ConsumerLab.com L. About ConsumerLab.com. 2016. http://www.consumerlab.com/aboutcl.asp - product reviews.

Download references

Author information

Authors and Affiliations

  1. Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Donna J. Stephenson & Amanda L. Hall

Authors
  1. Donna J. Stephenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amanda L. Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna J. Stephenson.

Ethics declarations

Conflict of Interest

Donna J. Stephenson is a section editor for Current Pediatric Reports.

Amanda L. Hall declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stephenson, D.J., Hall, A.L. An Integrative Approach to Pediatric Headache Management: Nutraceuticals. Curr Pediatr Rep 5, 77–85 (2017). https://doi.org/10.1007/s40124-017-0131-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40124-017-0131-x

Keywords

Search

Navigation